A medical professional will teach you how to self administer this safely. If you are uncomfortable with self administration, your family member, GP, nurse or neurologist could help with this.
Here are a few things to remember when injecting Ajovy:
- Ensure it is not expired or damaged. The liquid should be clear or slightly yellow, and check for cracks or leaks on the syringe.
- Hygiene is essential. Wash your hands before injecting, and wipe the injection site with an alcohol wipe beforehand.
- Dispose of sharps safely. All needles need to go in a sharps disposal container.
- You might have side effects. Pain, redness, and itching are all common injection site reactions. Keep a cold compress or ice pack at hand in case you experience these symptoms.
If you have been prescribed Ajovy, you can access more information at MigraineHQ – the dedicated patient website for Ajovy. Please note that you will need to enter the barcode number on the back of your Ajovy pack before you can access this website.
How effective is Ajovy?
Just like other migraine preventives, the efficacy of Ajovy can vary from person to person. Some might find it very effective, while others might find it doesn’t help much at all.
The tables below show the results of two clinical trials that measured the safety and efficacy of Ajovy. One study was for episodic migraine and the other was for chronic migraine, and both were conducted in a three month period. Participants either received a monthly 225 mg dose or a single dose of 675 mg at the start of the trial.
Episodic migraine (4)
| ||225 mg dose (n = 290)||675 mg dose (n = 291)||Placebo (n = 294)
|Average migraine days per month at baseline||8.9||9.3||9.1
|Average migraine days per month during treatment||4.7||5.3||6.4
|Average reduction in migraine days||‒4.2||‒4.0||‒2.7
|Percentage of patients with 50% or more reduction in monthly headache days||47.7%||44.4%||27.9%
Source: Clinical Trial Identifier NCT02629861 (4)
Chronic migraine (5)
| ||225 mg dose (n = 375)||675 mg dose (n = 375)||Placebo (n = 371)
|Average migraine days per month at baseline||16.0||16.2||16.4
|Average migraine days per month during treatment||11.0||11.3||13.2
|Average reduction in migraine days||‒5.0||‒4.9||‒3.2
|Percentage of patients with 50% or more reduction in monthly headache days||40.8%||37.6%||18.1%
Source: Clinical Trial Identifier NCT02621931 (5)
These studies show a clinically significant reduction in migraine days for people with both episodic or chronic migraine. However, if you try Ajovy and find that it doesn’t work for you, don’t be discouraged. Some people will not respond to one CGRP monoclonal antibody but find another very helpful. You can discuss your options with your doctor.